Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Long-standing efforts to develop drugs that target MEKs could soon come to fruition, moving the frontier to how best to combine them with other cancer therapies.
Less than a decade on from genetic studies indicating the potential of PCSK9 as a target to affect cholesterol metabolism, two PCSK9 inhibitors are moving into late-stage development.
The market for drugs to treat wet age-related macular degeneration (AMD) is expected to more than double by 2016. This article investigates unmet needs and discusses current agents in the pipeline.